Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Symbiotec Pharmalab Limited (NSE: SYMBIOTEC), ISIN INE899I01028 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
SYMBIOTEC last traded at ₹1279.50 (+1.96%), with a 52-week range of ₹933.80 to ₹1310.00 (as of 16 Oct 2026).
Shareholding as of Sep 2026: promoters 33.28%, FIIs 21.08%, DIIs 27.51%, mutual funds 5.54%.
EquiSense Score (ECS): 50/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.